Suzanne George
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Validation of predictive and prognostic biomarkers in patients with post-chemotherapy residual disease in A011202
Open Date: 2022-10-01
Close Date: 2024-09-30
Grant: Close
Clonal Hematopoiesis of Indeterminate Potential (CHIP), Obesity, and Breast Cancer Outcomes in the Breast Cancer Weight Loss (BWEL) Trial
Open Date: 2021-10-01
Close Date: 2023-09-30
Articles (50)
Year:
2026
Year:
2026
Year:
2025
Purpose: Cardiac angiosarcoma is a rare, aggressive malignancy with limited treatment options. Both sporadic and familial cases occur, with recent links to germline POT1 mutations. The genomic landscape of this disease is poorly understood. Experimental Design: We conducted comprehensive genomic profiling of cardiac angiosarcoma to assess the burden of germline predisposition and identify other recurrent genomic alterations of clinical significance. Results: Six patients were female, and four were male. The median age at presentation was 40 years (range, 21–69 years). All cases with available follow-up exhibited an aggressive clinical course (6/8 patients died of disease). KDR alterations, including novel structural variants, were found in 9/11 cases at a rate significantly higher than that in noncardiac angiosarcomas. POT1 mutations were present in 45.5% of cardiac angiosarcoma cases. In three of five POT1-mutant cases, the germline status was confirmed through testing of normal tissue, and in one additional case, the germline status was inferred with high probability through allele frequency analysis. Additionally, we identified novel recurrent MED12 exon 2 mutations in POT1 wild-type cardiac angiosarcoma, suggesting an alternative path to cardiac angiosarcoma oncogenesis. Conclusions: Cardiac angiosarcoma demonstrates a unique genetic profile, distinct from noncardiac angiosarcoma. This study highlights the role of germline POT1 burden on cardiac angiosarcoma development and demonstrates recurrent MED12 alterations for the first time. The reported KDR variants provide a potential avenue for the treatment of this aggressive disease. Given the prevalence of germline POT1 mutations reported in this study, germline genetic testing should be considered in patients diagnosed with cardiac angiosarcoma.
Year:
2025
GI stromal tumors (GISTs) are mesenchymal neoplasms with variable natural histories, originating in the GI tract, most commonly in the stomach. They are frequently characterized by KIT or platelet-derived growth factor receptor alpha ( PDGFRA ) oncogenic mutations. Surgical resection remains the cornerstone treatment for localized GISTs. Clinical trials have demonstrated the benefits of adjuvant imatinib in patients selected on the basis of recurrence risk and gene mutations, although the optimal duration of therapy is yet to be established. Some data suggest that longer durations of adjuvant imatinib (>3 years) may provide additional benefit, which is being investigated in ongoing trials. Management of imatinib-related adverse effects is essential during treatment, and longitudinal abdominal imaging is mandatory both during and after adjuvant therapy. Once GISTs are more advanced and unresectable, KIT- and PDGFRA-directed tyrosine kinase inhibitors (TKIs) become the key treatment in most patients with KIT mutation. Several TKIs have regulatory approval for advanced GISTs, but in most patients, resistance to TKIs eventually emerges, mainly from secondary resistance mutations in KIT . Each TKI has different coverage of oncogenic KIT mutations, suggested by preclinical and clinical findings, which has given rationale to an ongoing clinical trial that includes molecular selection as eligibility criteria. Furthermore, novel treatment approaches, from TKI combinations to an antibody-drug conjugate, are being investigated. Despite the significant advance in managing GISTs with KIT mutations, those without KIT or PDGFRA mutation, which consists of 10%-15% of patients with GIST, can be a clinical challenge in the advanced setting. These non- KIT/PDGFRA GISTs could be driven by genomic or epigenomic alterations in SDHx , NF1 mutations, and other genomic alterations. Non- KIT/PDGFRA GISTs are less responsive to currently available TKIs than GISTs driven by KIT/PDGFRA mutations, and each subset of non- KIT/PDGFRA GIST has distinctive biology and clinical features. Therefore, individualized, multidisciplinary, biology-based management and consideration for clinical trial enrollment are critical for non- KIT/PDGRFA GISTs.
Year:
2025
Supplementary Table S3: List of pathogenic or likely pathogenic mutations in LMS based on 1) ClinVar (20); 2) functional classification as deleterious by both SIFT (21) and PolyPhen (22); and 3) truncating nature of the mutation.
Year:
2025
Supplementary Figure S6 Representative cell culture images of LMS04 cultures untreated or treated with 2nM doxorubicin, 400 nM peposertib, or the combination of both, utilized for computationally assisted cell culture confluence analysis (See Supplementary Figure S7).
Year:
2025
Supplementary Figure S3: Mutated genes, fraction and counts of non-structural mutations in each gene (right) in clinical samples from 251 LMS tumors sequenced with OncoPanel. A. Alterations in TP53, RB1 and ATRX were detected in 73%, 73% and 31% of LMS, respectively, including single copy deletions and low amplitude gains; B. Alterations in genes mutated in >4% of samples, excluding single copy deletions and low amplitude gains. Deleterious mutations impacting BRCA2 or BRCA1 were demonstrated in 49% of LMS and were most often heterozygous deletions, whereas 8% of LMS had identifiable BRCA1/BRCA2 intragenic mutations or homozygous deletions. As with other targeted NGS platforms, these findings underestimate the true frequency of TP53 and RB1 mutations, given challenges detecting inactivating structural variants, particularly in large genes such as RB1.
Year:
2025
Supplementary Figure S8: Synergistic effects of peposertib and low-dose doxorubicin combinations in LMS cells. Cell proliferation assay (BrdU incorporation) demonstrates that addition of low-dose doxorubicin to DNA-PKi treatment results in synergistic effects on LMS03, LMS04 and LMS05 cell proliferation. Cells were treated for 7 days with the drug combinations at the indicated doses; BrdU incorporation over 24h was measured at day 7 with a luminescence-based ELISA assay (Roche). Synergy scores and heatmap / surface plots were generated using SynergyFinder (RRID:SCR_019318)(35).
Year:
2025
Supplementary Figure S1: A. Fraction of genome altered (FGA) in non-LMS cancers compared to LMS from GENIE v9.0 (37). B. FGA in LMS and in other tumor types in the GENIE dataset, including high grade sarcomas.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (39)
Heikki Joensuu
University of Helsinki
Karla Ballman
Chair / Consultant / Professor of Biostatistics
Mayo Clinic College of Medicine and Science
Sandro Santagata
Brigham and Women's Hospital
Frank Tadashi Zenke
Chief Scientific Officer
-
Julia Glade Bender
Vice Chair for Clinical Research
Memorial Sloan Kettering Cancer Center
Neeta Somaiah
Professor and Chair
The University of Texas MD Anderson Cancer Center
Douglas Hawkins
Professor
University of Washington
Michael Wagner
Dana-Farber Cancer Institute
Thierry Alcindor
McGill University Health Centre
Igor Odintsov
Assistant Professor
University of California, San Francisco
Lori Rink
Associate Professor
Fox Chase Cancer Center
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Peter Park
Harvard University
Yoon-Koo Kang
Professor
Asan Medical Center
Margaret von Mehren
Professor
Fox Chase Cancer Center
jordan Berlin
Professor
Vanderbilt University Medical Center
James Ford
Professor
Stanford University
Joseph Michael Unger
Fred Hutchinson Cancer Research Center
Eric Tetzlaff
Physician Assistant, Assistant Professor
Fox Chase Cancer Center
Gary Lyman
Fred Hutchinson Cancer Research Center
Jason Sicklick
University of California, San Diego
Robert Gray
Dana-Farber Cancer Institute
John R. Zalcberg
-
Melissa Burgess
University of Pittsburgh
Gabriel Tinoco
Associate Professor of Medicine
Ohio State University
Petros Grivas
University of Washington
Robert G. Maki
Professor, Member
-
Peter Sorger
Otto Krayer Professor of Systems Pharmacology
Harvard Medical School
Robin Jones
Consultant Medical Oncology, Head of Sarcoma Unit
Royal Marsden NHS Foundation Trust
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Michael C. Heinrich
Oregon Health & Science University
Hans Gelderblom
Prof.dr
Leiden University Medical Center
Sebastian Bauer
Professor / Chair
Universität Duisburg-Essen
Cesar Serrano
External Group Leader (TRIP-Clinic program)
IRB Barcelona
Jean-Yves Blay
University Professor, Medical Oncology
Université Claude Bernard Lyon 1 - Domaine de Rockefeller
Elizabeth Davis
Vanderbilt University Medical Center
Edwin Choy
Associate Professor
Harvard Medical School
Timothy Yap
The University of Texas MD Anderson Cancer Center
Elizabeth Handorf
Associate Professor
Rutgers, The State Univ. of NJ
Make your next move.
Prepare your application
Review drafts before you send them.